Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Merus NV MRUS

Healthcare Biotechnology
Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.


NDAQ:MRUS - Post by User

Merus NV
Bullboard Posts
User Avatar Image
(119)
•••
Post by whytestockson May 28, 2024 10:00pm
43 Views
Post# 36061535

MRUS Price Target Alert: $84.00. Issued by BMO Capital

MRUS Price Target Alert: $84.00. Issued by BMO Capital
Breaking News: $MRUS MRUS Price Target Alert: $84.00. Issued by BMO Capital2024-05-28 14:00:08 ET Etzer Darout from BMO Capital issued a price target of $84.00 for MRUS on 2024-05-28 11:51:00. The adjusted price target was set to $84.00. At the time of the announcement, MRUS was trading at $53.86. The overall price target consensus is at $61.75...MRUS - MRUS Price Target Alert: $84.00. Issued by BMO Capital

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities